mpiloは、医療専門家向けのAI搭載医療アシスタントです。患者との診察内容をリアルタイムで聞き取り、SOAPノートなど、正確でHIPAAに準拠した臨床記録を自動で作成します。文書作成を自動化することで、mpiloは管理業務の負担を軽減し、燃え尽き症候群を最小限に抑え、臨床医がより患者ケアに集中できるようにします。安全で様々な専門分野に適応し、独自の文書スタイルを学習して、シームレスなワークフロー統合を実現します。
Sukiは、臨床医向けのエンタープライズグレードのAI搭載音声対応デジタルアシスタントです。アンビエントAIを使用して、臨床文書作成、コーディング、処方箋入力などの管理業務を自動化します。Sukiは主要な電子カルテ(EHR)と深く統合し、臨床医の燃え尽き症候群を軽減し、時間を節約し、患者ケアに集中できるようにします。
製品概要
mpilo 製品概要
mpiloは、医療専門家向けのAI搭載医療アシスタントです。患者との診察内容をリアルタイムで聞き取り、SOAPノートなど、正確でHIPAAに準拠した臨床記録を自動で作成します。文書作成を自動化することで、mpiloは管理業務の負担を軽減し、燃え尽き症候群を最小限に抑え、臨床医がより患者ケアに集中できるようにします。安全で様々な専門分野に適応し、独自の文書スタイルを学習して、シームレスなワークフロー統合を実現します。
Suki 製品概要
Sukiは、臨床医向けのエンタープライズグレードのAI搭載音声対応デジタルアシスタントです。アンビエントAIを使用して、臨床文書作成、コーディング、処方箋入力などの管理業務を自動化します。Sukiは主要な電子カルテ(EHR)と深く統合し、臨床医の燃え尽き症候群を軽減し、時間を節約し、患者ケアに集中できるようにします。
Detailed feature comparison
mpilo vs Suki monthly traffic
Compare mpilo and Suki by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
How to interpret the traffic data
In the mpilo vs Suki monthly traffic comparison, mpilo currently shows 3.3K visits and Suki shows 47K; Suki has about 14.1 times the visible traffic of mpilo, an absolute difference of about 43.7K visits. This reflects visible reach, not feature quality or paid users.
Only Suki has complete third-party traffic details; mpilo uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
mpilo monthly traffic:
Latest traffic
Suki monthly traffic:
Latest traffic
Monthly traffic trend
- 2025/9: 77.8K 月間訪問数
- 2026/1: 76.9K 月間訪問数
- 2026/2: 62.3K 月間訪問数
- 2026/3: 58.8K 月間訪問数
- 2026/4: 58.5K 月間訪問数
- 2026/5: 47K 月間訪問数
主要地域
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 53.6% | 25.2K |
| 🇮🇳India | 27.04% | 12.7K |
| 🇻🇳Vietnam | 8.34% | 3.9K |
| 🇨🇦Canada | 5.61% | 2.6K |
| 🇪🇬Egypt | 5.41% | 2.5K |
流入元
| Source type | Percentage | Traffic |
|---|---|---|
| ダイレクト | 84.28% | 39.6K |
| 参照元 | 13.53% | 6.4K |
| Eメール | 2.19% | 1K |
検索キーワード
Usage comparison
Compare the core capabilities of mpilo and Suki
mpilo Core features
Suki Core features
Use cases
mpilo Use cases
Suki Use cases
mpilo vs Suki:In-depth comparison and selection guidance
First decide whether the products solve the same kind of need
This in-depth mpilo vs Suki comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. mpilo is primarily listed under “臨床アシスタント”, while Suki is primarily listed under “臨床アシスタント”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Pricing (mpilo: Freemium; Suki: Paid); Monthly visits (mpilo: 3.3K; Suki: 47K); Favorites (mpilo: 115; Suki: 133); Website (mpilo: mpilo.ai; Suki: www.suki.ai); Added (mpilo: 2025-08-03; Suki: 2025-08-14). These facts are more useful for selection than brand visibility alone.
What market visibility and monthly traffic mean
In the mpilo vs Suki monthly traffic comparison, mpilo currently shows 3.3K visits and Suki shows 47K; Suki has about 14.1 times the visible traffic of mpilo, an absolute difference of about 43.7K visits. This reflects visible reach, not feature quality or paid users.
Only Suki has complete third-party traffic details; mpilo uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
The current traffic scope is not sufficient for a reliable product ranking. Treat monthly visits as a market-interest signal, then decide using taxonomy, use cases, pricing, and a like-for-like trial rather than reading exposure as product capability.
Product positioning, use cases, and roles
mpilo and Suki currently overlap in shared categories: 臨床アシスタント、医療文書、文字起こし; shared tags: ヘルスケア、医療クラーク、医療転写. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
mpilo's unique categories/tags are 診療記録、臨床医のバーンアウト、医師アシスタント、電子健康記録、HIPAA、患者記録、SOAPノート; Suki's are アンビエントAI、臨床文書、電子カルテ連携、ICD-10コーディング、医療助手、医師の燃え尽き症候群、音声認識. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
What ratings, comments, and favorites can tell you
mpilo has no verified rating, 0 comments, 115 favorites, and 122 likes;Suki has no verified rating, 0 comments, 133 favorites, and 130 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Selection guidance by actual need
When to evaluate mpilo first
Put mpilo on the priority trial list when the task aligns with “臨床アシスタント” and especially 診療記録、臨床医のバーンアウト、医師アシスタント、電子健康記録、HIPAA、患者記録. This follows recorded positioning and does not imply unlisted capabilities are absent.
mpilo also currently records: pricing is freemium, product type is website, 3.3K on-site monthly views, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
When to evaluate Suki first
Put Suki on the priority trial list when the task aligns with “臨床アシスタント” and especially アンビエントAI、臨床文書、電子カルテ連携、ICD-10コーディング、医療助手、医師の燃え尽き症候群. This follows recorded positioning and does not imply unlisted capabilities are absent.
Suki also currently records: pricing is paid, product type is website, 47K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
How to validate the recommendation before deciding
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in mpilo and Suki, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.




